Pioglitazone (potassium)

Pioglitazone (potassium)

• CAS Number: 1266523-09-4
• UNSPSC Description: Pioglitazone (U 72107) potassium is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 μM and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone potassium can be used in diabetes research[2][3][4].
• Target Antigen: Ferroptosis; PPAR
• Type: Reference compound
• Related Pathways: Apoptosis;Cell Cycle/DNA Damage;Metabolic Enzyme/Protease;Vitamin D Related/Nuclear Receptor
• Applications: Metabolism-sugar/lipid metabolism
• Field of Research: Cancer; Metabolic Disease
• Assay Protocol: https://www.medchemexpress.com/pioglitazone-potassium.html
• Solubility: 10 mM in DMSO
• Smiles: CCC1=CC=C(N=C1)CCOC2=CC=C(C=C2)CC(SC([N-]3)=O)C3=O.[K+]
• Molecular Weight: 394.53
• References & Citations: [1]Kenji Kuwabara, et al. A novel selective peroxisome proliferator-activated receptor alpha agonist,2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose levels and modifies lipoprotein profiles in KK-Ay mice. J Pharmacol Exp Ther. 2004 Jun;309(3):970-7.|[2]A Puddu, et al. Pioglitazone attenuates the detrimental effects of advanced glycation end-products in the pancreatic beta cell line HIT-T15. Regul Pept. 2012 Aug 20;177(1-3):79-84.|[3]Naoto Kubota, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem. 2006 Mar 31;281(13):8748-55.|[4]Rania A Elrashidy, et al. Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):324-33.
• Shipping Conditions: Room temperature
• Clinical Information: Launched